Teva Pharmaceutical/$TEVA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Teva Pharmaceutical

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Ticker

$TEVA

Primary listing

NYSE

Industry

Pharmaceuticals

Headquarters

Tel Aviv, Israel

Employees

37,000

TEVA Metrics

BasicAdvanced
$19B
-
-$1.14
0.61
-

What the Analysts think about TEVA

Analyst ratings (Buy, Hold, Sell) for Teva Pharmaceutical stock.

Bulls say / Bears say

Teva's cost-cutting initiatives, including a $700 million program, are expected to improve operating margins and fund pipeline programs, with JPMorgan upgrading the stock to 'overweight' and raising the price target to $23. (finviz.com)
The company's specialty drug Austedo reported a 39% increase in worldwide revenue, reaching $411 million in Q1 2025, indicating strong growth in high-margin products. (finviz.com)
Teva's divestiture of its active pharmaceutical ingredient business is seen as a strategic move to focus on core operations, leading to a 2.7% premarket stock rise upon announcement. (tradingview.com)
Teva's Q4 2024 adjusted earnings declined by 29% year-over-year, with revenues falling 5%, partly due to the absence of a $500 million upfront payment received in the prior-year quarter. (nasdaq.com)
The company faced a legal setback when the U.S. Court of Appeals upheld Johnson & Johnson's patent on Invega Sustenna, preventing Teva from producing a generic version and limiting potential revenue streams. (reuters.com)
Teva's stock declined by 13.5% following the release of Q4 earnings, reflecting investor concerns over the company's financial performance and future outlook. (fool.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.

TEVA Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

TEVA Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TEVA

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events
FAQs